<DOC>
	<DOCNO>NCT00014534</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Randomized phase III trial compare different combination chemotherapy regimens treat patient advanced bladder cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare survival patient completely resect locally advanced transitional cell carcinoma bladder treat adjuvant doxorubicin gemcitabine follow paclitaxel cisplatin v adjuvant cisplatin gemcitabine . Secondary - Compare toxicity profile regimens patient . OUTLINE : This randomize study . Patients stratify accord primary tumor status ( &lt; T4 v T4 ) , number positive lymph node ( 0 unknown vs 1-5 v &gt; 5 ) , number dissect node ( 0-10 unknown v &gt; 10 ) . Patients randomize one two treatment arm . - Arm I : Patients receive adjuvant gemcitabine IV 30 minute day 1 , 8 , 15 cisplatin IV 30-60 minute day 1 . Treatment repeat every 4 week 4 course absence disease progression unacceptable toxicity . - Arm II : Patients receive adjuvant doxorubicin IV 45 minute follow gemcitabine IV 2 hour day 1 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily day 3-10 . Treatment repeat every 14 day 4 course absence disease progression unacceptable toxicity . Beginning 14 day completion doxorubicin gemcitabine , patient receive paclitaxel IV 3 hour cisplatin IV 20-30 minute day 1 . Patients also receive G-CSF SC daily day 3-10 4-11 . Treatment repeat every 14 day 4 course absence disease progression unacceptable toxicity . Patients follow every 3 month 18 month , every 6 month 18 month , annually thereafter .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma bladder Any T , N+ , M0 OR T3a4a , N0 , M0 At least 6 week 3 month since prior complete resection bladder Cystoprostatectomy plus pelvic lymph node dissection male Cystectomy/total abdominal hysterectomy/bilateral salpingooophorectomy plus pelvic lymph node dissection female Negative surgical margin Carcinoma situ allow No partial cystectomy transurethral bladder tumor resection definitive locoregional therapy Prostate cancer detect resected specimen allow postoperative PSA 0.05 mg/dL No metastatic recurrent disease postoperative chest xray CT scan abdomen pelvis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Hematopoietic : Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 150,000/mm^3 Hepatic : Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2 time ULN AST ≤ 2 time ULN Renal : Creatinine ≤ 1.5 mg/dL OR Creatinine clearance ≥ 60 mL/min Cardiovascular : Normal cardiac function history , physical exam , chest radiograph Left ventricular ejection fraction least 50 % radionuclide ventriculogram echocardiogram , prior cardiac disease No New York Heart Association class III IV heart disease No serious cardiac arrhythmia include first , second , thirddegree heart block Other : Negative pregnancy test No uncontrolled infection No active cancer within past 5 year except nonmelanoma skin cancer curatively treat carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy bladder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>